Behaviors and Mental Disorders

All Conditions

Symptoms and General Pathology

Wounds and Injuries

Neoplasms

Digestive System Diseases

Cognitive Dysfunction

Hyperthermia

Fever

Postoperative Cognitive Complications

Peritoneal Neoplasms

Cognition Disorders

Neurocognitive Disorders

Mental Disorders

Psychotic Disorders

Postoperative Complications

Abdominal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Peritoneal Diseases

Mian Peng, Doctor

Objectives to investigate the incidence and associated factors for early postoperative cognitive dysfunction in the patients with peritoneal surface malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemo-therapy(CRS-HIPEC).Methods fifty patients aged 18-65 yr were included in the research and were grouped base on the score of neuropsychological assessments which had done in the ward at 7 day before and after the surgery. The investigators monitored various indicators in the perioperative period, such as age, body weight, sex, education, duration of operation, intraoperative blood loss, cardiovascular events, amount of fluid infused per hour. Meanwhile, the concentration of serum amploid A (SAA),IL-1beta,TNF-alpha,HMGB1,S100b,cortisol and Abeta40 were measured at the various stage of the operation and 24 hours after the operation, and the differences of data between postoperative cognitive dysfunction(POCD) and Non-POCD groups were analyzed.

Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC

Risk Factors for Early POCD(Postoperative Cognitive Dysfunction) in the Patients With PSM(Peritoneal Surface Malignancies )Undergoing CRS(Cytoreductive Surgery) and HIPEC(Hyperthermic Intraperitoneal Chemo-therapy)

Wuhan University

Doctor

Adjuvants, Anesthesia

Analgesics

Central Nervous System Depressants

All Drugs and Chemicals

Antiemetics

Gastrointestinal Agents

Fentanyl

Neostigmine

Palonosetron

Remifentanil

Glycopyrrolate

Desflurane

At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.

HIPEC cytoreductive surgery

The most popular surgical treatment of peritoneal cancer is the type known as hyperthermic intraperitoneal chemoperfusion (HIPEC), a type of cytoreductive surgery for which a significantly high survival rate has been demonstrated by several studies. It is widely known that HIPEC entails severe physiological changes and precautions during anesthesia. However, very few studies have systematically outlined and organized these changes for each system, and most existing studies only report retrospective data or are limited to gynecological surgeries. Therefore, the present researchers planned a prospective observational study to determine the physiological changes that occur in patients during HIPEC cytoreductive surgeries performed in the colon and rectal surgery department of the investigators hospital. The investigators planned to monitor the patients' body temperature, metabolism, cardiovascular and respiratory changes during HIPEC cytoreductive surgery and analyze the anesthetic methods applied to identify the optimal anesthetic management strategy for HIPEC cytoreductive surgeries.

The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study

Yonsei University

Inflammation

Body Temperature Changes

Stress Disorders, Traumatic

Heat Stress Disorders

Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy

During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy

CRS and HIPEC

Kuno Lehmann, MD, PhD

Dilmurodjon Eshmuminov, MD

Kuno Lehmann, Md. PhD

The purpose of this study is to assess the dynamics of inflammatory parameters in presence or absence of infectious complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the treatment of choice in patients with primary or secondary peritoneal surface malignancies. However the survival benefit is achieved at the cost of increased morbidity and mortality due to an extensive surgery and intraoperative chemo-therapy. Among complications infectious complications are the most common. The early diagnosis of a potential fatal infection is therefore crucial to ensure a good outcome in patients.

Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

University of Zurich

Rare Diseases

Stomach Neoplasms

Carcinoma

Stomach Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Stomach Cancer

Antineoplastic Agents

Micronutrients

Docetaxel

Oxaliplatin

Leucovorin

Fluorouracil

Tubulin Modulators

Antimitotic Agents

Participants will receive intraperitoneal docetaxel combined with the standard of care. A standard 3 + 3 dose escalation design will be used according to the dose escalation plan.

Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).

Intraperitoneal docetaxel

Fabian M Johnston, MD, MHS

Sherry Leung

Fabian M Johnston, M.D., M.H.S., F.A.C.S

Sherry G Leung

This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).

Gastric cancer (GC) is one of the leading causes of cancer-related deaths in the United States and has a five-year survival of 40% after surgical resection. Metastatic gastric cancer has an even poorer prognosis and most patients die within the first year of diagnosis. Most patients are diagnosed in advanced stages of the disease due to non-specific or lack of symptomatology and treatment options are then limited to systemic chemotherapy. The peritoneum is the most frequent site of metastasis as well as cancer recurrence. Peritoneal Carcinomatosis (PC) results in adverse clinical sequelae and is ultimately responsible for 60% of all gastric cancer-related deaths. While visceral metastases originating from primary gastric cancer are relatively chemosensitive, peritoneal carcinomatosis is particularly challenging to treat because of inadequate drug delivery from systemic circulation. The primary purpose of this trial is to determine the safety of administering intraperitoneal docetaxel in conjunction with the standard of care treatment regimen of intravenous mFOLFOX6 (5-Fluorouracil, leucovorin, and oxaliplatin) in patients with primary gastric cancer with gross peritoneal carcinomatosis.

Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis

A Phase I Study of Intraperitoneal Docetaxel in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) for Gastric Cancer Patients With Peritoneal Carcinomatosis

To determine the Maximum Tolerated Dose (MTD) of intraperitoneal docetaxel in conjunction with the standard of care treatment regimen of intravenous mFOLFOX6 in patients with primary gastric cancer with gross peritoneal carcinomatosis

Progression-free survival rate at 20 weeks, which is defined as the percentage of patients alive and free of disease progression at 20 weeks.

Johns Hopkins University

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Blood and Lymph Conditions

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Immune System Diseases

Diseases and Abnormalities at or Before Birth

Nervous System Diseases

Nutritional and Metabolic Diseases

Musculoskeletal Diseases

Syndrome

Nasopharyngeal Carcinoma

Esophageal Neoplasms

Leukemia

Cholangiocarcinoma

Breast Neoplasms

Pancreatic Neoplasms

Melanoma

Skin Neoplasms

Prostatic Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Sarcoma

Carcinoma, Renal Cell

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Multiple Myeloma

Neoplasms, Plasma Cell

Adenomatous Polyposis Coli

Urinary Bladder Neoplasms

Vaginal Neoplasms

Gastrointestinal Stromal Tumors

Liver Neoplasms

Neuroendocrine Tumors

Thyroid Nodule

Mesothelioma

Mesothelioma, Malignant

Duodenal Neoplasms

Mouth Neoplasms

Thymoma

Thymus Neoplasms

Central Nervous System Neoplasms

Testicular Neoplasms

Kidney Neoplasms

Anus Neoplasms

Nervous System Neoplasms

Endometrial Neoplasms

Salivary Gland Neoplasms

Gallbladder Neoplasms

Oropharyngeal Neoplasms

Bile Duct Neoplasms

Nasopharyngeal Neoplasms

Urethral Neoplasms

Laryngeal Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms, Hereditary Nonpolyposis

Hypopharyngeal Neoplasms

Intestinal Neoplasms

Penile Neoplasms

Ureteral Neoplasms

Neoplasms, Unknown Primary

Paranasal Sinus Neoplasms

Lip Neoplasms

Paraproteinemias

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Male Urogenital Diseases

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Genital Diseases, Female

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Gonadal Disorders

Neoplasms, Connective and Soft Tissue

Rectal Neoplasms

Intestinal Diseases

Rectal Diseases

Urologic Neoplasms

Urologic Diseases

Colonic Diseases

Head and Neck Neoplasms

Esophageal Diseases

Ken Cowan, MD

Michelle M Desler, MS

Jeannie Robbins

Noelle Beauchemin, MD

Sandy Allten, RN

Erik Harris, MD

Sandra Allten, RN,OCN,CCRP

Kellie Hyde

Luke Hazen

Joseph Meschi, MD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC	NCT02462564	Postoperative C...		18 Years - 65 Years	Wuhan University
Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC	NCT02462564	Postoperative C...		18 Years - 65 Years	Wuhan University
The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study	NCT02325648	Peritoneal Surf...	HIPEC cytoreduc...	20 Years -	Yonsei University
Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	NCT02741167	Peritoneal Canc...	CRS and HIPEC	18 Years -	University of Zurich
Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	NCT02741167	Peritoneal Canc...	CRS and HIPEC	18 Years -	University of Zurich
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis	NCT04583488	Peritoneal Carc...	Intraperitoneal...	18 Years -	Johns Hopkins University
Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy	NCT02741167	Peritoneal Canc...	CRS and HIPEC	18 Years -	University of Zurich
Integrated Cancer Repository for Cancer Research	NCT02012699	Pancreatic Canc... Thyroid Cancer Lung Cancer Esophageal Canc... Thymus Cancer Colon Cancer Rectal Cancer Gastrointestina... Anal Cancer Bile Duct Cance... Duodenal Cancer Gallbladder Can... Gastric Cancer Liver Cancer Small Intestine... Peritoneal Surf... Familial Adenom... Lynch Syndrome Bladder Cancer Kidney Cancer Penile Cancer Prostate Cancer Testicular Canc... Ureter Cancer Urethral Cancer Hypopharyngeal ... Laryngeal Cance... Lip Cancer Oral Cavity Can... Nasopharyngeal ... Oropharyngeal C... Paranasal Sinus... Nasal Cavity Ca... Salivary Gland ... Skin Cancer Central Nervous... Central Nervous... Mesothelioma Breast Cancer Leukemia Melanoma Sarcoma Unknown Primary... Multiple Myelom... Ovarian Cancer Endometrial Can... Vaginal Cancer Neuroendocrine ... Plasma Cell Dys... Healthy Control		19 Years - 110 Years	University of Nebraska

Spots Global Cancer Trial Database for peritoneal surface malignancies